JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Search

IQVIA Holdings Inc

Suletud

SektorTervishoid

213.83 -1.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

207.47

Max

216.46

Põhinäitajad

By Trading Economics

Sissetulek

17M

266M

Müük

188M

4B

P/E

Sektori keskmine

31.928

37.003

Kasumimarginaal

6.622

Töötajad

90,000

EBITDA

28M

781M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+9.63% upside

Turustatistika

By TradingEconomics

Turukapital

10B

37B

Eelmine avamishind

215.05

Eelmine sulgemishind

213.83

Uudiste sentiment

By Acuity

50%

50%

142 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

IQVIA Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2025, 21:44 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3. nov 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3. nov 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3. nov 2025, 23:28 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3. nov 2025, 23:24 UTC

Tulu

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

3. nov 2025, 23:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3. nov 2025, 23:12 UTC

Tulu

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3. nov 2025, 23:06 UTC

Market Talk
Tulu

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3. nov 2025, 22:36 UTC

Market Talk
Tulu

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q EPS $1.49 >FNV

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q Rev $487.7M >FNV

3. nov 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3. nov 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Starbucks Agrees to Sell Stake in China Business -- WSJ

3. nov 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk
Tulu

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

3. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. nov 2025, 21:49 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3. nov 2025, 21:40 UTC

Tulu

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3. nov 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3. nov 2025, 21:19 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3. nov 2025, 21:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3. nov 2025, 21:11 UTC

Tulu

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3. nov 2025, 21:07 UTC

Tulu

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3. nov 2025, 21:05 UTC

Tulu

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. nov 2025, 21:05 UTC

Tulu

Palantir Technologies 3Q Net $475.6M >PLTR

Võrdlus sarnastega

Hinnamuutus

IQVIA Holdings Inc Prognoos

Hinnasiht

By TipRanks

9.63% tõus

12 kuu keskmine prognoos

Keskmine 237.31 USD  9.63%

Kõrge 265 USD

Madal 200 USD

Põhineb 15 Wall Streeti analüütiku instrumendi IQVIA Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

12

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

150.68 / 153.45Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

142 / 373 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat